Codexis

Codexis Debt

The Debt of Codexis (CDXS) as of Sep 26, 2026 is 73.21 M USD. In the previous year, Debt was 59.90 M USD — a change of 22.23% (higher).

Debt

73.21 MUSD

YoY

22.23%

Last updated:

In 2026, Codexis's total debt was 73.21 M USD, a 22.23% change from the 59.90 M USD total debt recorded in the previous year.

The Codexis Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
486,000.00 USD
Jan 1, 2019
26.12 M USD
Jan 1, 2020
24.95 M USD
Jan 1, 2021
47.65 M USD
Jan 1, 2022
43.64 M USD
Jan 1, 2023
16.02 M USD
Jan 1, 2024
59.90 M USD
Jan 1, 2025
73.21 M USD
The Codexis Debt history
YEARDebtYoY
73.21 MUSD+22.23%
59.90 MUSD+273.78%
16.02 MUSD-63.28%
43.64 MUSD-8.43%
47.65 MUSD+90.99%
24.95 MUSD-4.47%
26.12 MUSD+5,274.07%
486,000.00USD-33.15%
727,000.00USD+71.06%
425,000.00USD0.00%
425,000.00USD—
0.00USD—
Access this data via the Eulerpool API

Codexis Stock analysis

What does Codexis do? Codexis Inc. is an American biotechnology company that specializes in developing innovative biological solutions for a variety of industries. The company was founded in 2002 and is headquartered in Redwood City, California. Business Model: Codexis is service-oriented and provides customized enzyme solutions for companies looking to improve their products through sustainable processes. The company has developed a unique platform called Rational Protein Engineering, which allows for the development of specific enzymes for various industries. Customers benefit from enzyme optimization expertise and know-how. Divisions: Codexis operates in the fields of life sciences, materials science, agrochemicals, and biofuels. 1. Life Sciences: Codexis specializes in the production of enzymes and biocatalysts for the pharmaceutical industry in the life sciences division. The goal is to provide a faster and more efficient manufacturing process for pharmaceutical active ingredients. The company has successfully developed active ingredients for antibodies, lipids, uric acid, and antivirals. 2. Materials Science: In the materials science division, Codexis specializes in the production of enzymes for materials such as dyes, polymers, and cosmetic products. Codexis ensures that these products are efficiently manufactured without the use of environmentally harmful chemicals. 3. Agrochemicals: Codexis offers customized enzyme solutions to agrochemical manufacturers that reduce the use of chemicals and benefit the environment. These enzymes help in the production of pesticides and other agrochemicals. 4. Biofuels: In the biofuels division, Codexis specializes in the production of enzymes for processing corn, harvested plants, or waste products. These enzymes help enable cost-effective biofuel production. Products: Codexis has developed a wide range of products tailored to the needs of various industries. Some of the products recently introduced to the market by Codexis include: 1. CodeEvolver: CodeEvolver is a platform that allows biotechnology companies to quickly create customized enzyme solutions for their specific needs. The process is fully automated and results in a significant reduction in development time and costs. 2. Codex® screening panels: Codexis offers various screening panels that allow customers to quickly and efficiently select the enzymes best suited for their purposes. The panels are suitable for industries including pharmaceuticals, chemicals, and plant protection. 3. Codex® enzymes: Codexis offers a wide range of enzymes specifically designed for different industry needs. This includes enzymes for the production of biofuels, pesticides, cosmetic products, and pharmaceuticals. Overall, Codexis Inc. has demonstrated its ability to deepen the understanding of biocatalysts and introduce innovative biological processes in a variety of industries through its unique Rational Protein Engineering platform. Codexis is one of the most popular companies on Eulerpool.

Debt Details

Understanding Codexis's Debt Structure

Codexis's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Codexis's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Codexis’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Codexis’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Codexis stock

Debt of Codexis is 73.21 M USD in 2026.

Debt of Codexis changed from 59.90 M USD to 73.21 M USD, representing a 22.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Codexis since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Codexis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Codexis

All Key Metrics — Codexis